All In Biotech

Drug Trial Radar · NCT04725175

Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of PIPE-307 and Food Effect in Normal Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Feb 26, 2021

Primary completion

Sep 1, 2021

Study completion Sep 1, 2021

Sponsor

Lead sponsor
Contineum TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind study of PIPE-307 or placebo in normal healthy subjects. The study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD) study enrolling approximately 48 subjects for a total duration of 6 weeks. Part 2 will be a Multiple Ascending Dose (MAD) study enrolling approximately 24 subjects for a total duration of 7 weeks, and part 3 will be a selected SAD cohort in a fed state to evaluate the effect of food on the bioavailability of PIPE-307, enrolling approximately 8 subjects from a selected SAD cohort for a duration of 6 weeks.

Conditions

  • Multiple Sclerosis

Interventions

  • PIPE-307Drug

    Single and multiple ascending oral doses of PIPE-307 tablets

  • Placebo oral tabletDrug

    Single and multiple ascending oral doses of matching Placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Treatment-Emergent Adverse Events (TEAE)Time frame: From baseline to 7 days post dosing for SAD cohorts and 21 days post dosing for MAD cohorts

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.